ClinicalTrials.gg
RecruitingNCT04421820Updated Oct 28, 2026

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

A Phase 1/2 interventional study of BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII) and BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) in Colorectal Cancer, Pancreatic Cancer and Gastric Cancers, sponsored by Bold Therapeutics, Inc.. Recruiting at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Bold Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.
Updated Oct 28, 2026First site in United KingdomSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 379 studies in Colorectal Neoplasms with a site in Canada — 72 open to participants now, 116 under way, 12 of them phase 3. Colorectal Neoplasms · Canada.

Planned enrollment
129th of 324
220 · median 151
Started
2020
with 15 others
Phase 1/2
39 of 379
12 open now
Primary completion
2027-07
later than 57 of 115 live
Registered
257th of 379
by date

Among the 379 studies in Colorectal Neoplasms with a site in Canada, this one is the 129th largest by planned enrollment of the 324 interventional ones that give a count, is one of 16 that started in 2020, is one of 39 in phase 1/2, reaches primary completion later than 57 of the 115 other live ones, and was the 257th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

72 of the 379 studies in Colorectal Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 379 studies in Colorectal Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX ± Bevacizumab chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase. This study now includes as a treatment intervention the SOC combination FOLFOX ± Bevacizumab, if indicated.

Read the detailed description

BOLD-100 is a novel, targeted anti-cancer therapy which is an intravenously administered small molecule drug. In a previous Phase 1 study (NCT01415297) BOLD-100 showed low toxicity with minimal hematological issues as well as some potential anti-tumour activity. The lack of observed hematological toxicity and neurotoxicity position BOLD-100 well for use in combination with a broad range of standard-of-care (SOC) chemotherapy regimens.

This is a prospective, multicenter non-randomized Phase 1b/2a dose escalation \& expanded cohort study of BOLD-100 in patients with advanced gastrointestinal malignancies (colorectal, pancreatic, gastric cancers, and cholangiocarcinoma) receiving standard-of-care FOLFOX chemotherapy. Enrollment in Arms I - VI is closed to enrollment.

Colorectal cancer (ARM VII) for patients who are oxaliplatin naïve and have received only 1 prior line of therapy in the metastatic setting. Within this arm, participants will be randomized to one of two dose levels of BOLD-100 - either 500 mg/m2 or 625 mg/m2 in combination with FOLFOX ± Bevacizumab or FOLFOX alone, in a 1:1:1 ratio. Participants enrolled into Arm VII will complete quality of life questionnaires examining general quality of life and neuropathy associated quality of life parameters. Participants will be eligible to receive the monoclonal antibody Bevacizumab as part of the standard of care treatment regimen (FOLFOX) if indicated.

03

Conditions studied

  • Colorectal Cancer
  • Pancreatic Cancer
  • Gastric Cancers
  • Cholangiocarcinoma
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 18 years or older.
  2. Be male or non-pregnant females who agree to comply with applicable requirements of the protocol.
  3. and/or cytologically confirmed gastrointestinal tumours that are or unresectable, and are subject to receive FOLFOX ± Bevacizumab. (ARM VII): Patients must have received only 1 in the metastatic setting.
  4. Have according to v1.1.
  5. Have an anticipated survival of at least 16 weeks.
  6. Be ambulatory, with an performance score of 0 or 1.
  7. Have adequate organ function.
  8. Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion.
  9. Be fully informed about their illness and the nature of the study protocol, and sign a REB-approved Form (ICF).
  10. (ARM VII): BRAF wild-type tumour status.

Exclusion criteria

Exclusion Criteria:

  1. Neuropathy > grade 2
  2. Previous intolerance to or significant reaction secondary to fluorouracil, oxaliplatin, or bevacizumab.
  3. Cerebrovascular accident within the past 6 months before the start of treatment.
  4. History or presence of central nervous system (CNS) or tumours.
  5. Any serious medical conditions that might be aggravated by treatment or limit compliance.
  6. Any history of serious cardiac illness.
  7. Hemoptysis, cerebral, or gastrointestinal hemorrhage in the past 6 months before the start of treatment.
  8. Any other known within 3 years before the start of treatment.
  9. Active gastrointestinal tract disease with malabsorption syndrome.
  10. Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease.
  11. Treatment with radiation therapy or surgery within 4 weeks prior to starting treatment.
  12. Recent history of weight loss > 10% of current body weight in past 3 months before the start of treatment.
  13. -positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
  14. Concurrent use of another therapy or anti-cancer therapy within 4 weeks before the start of treatment.
  15. Currently breastfeeding
  16. Dihydropyrimidine Dehydrogenase (DPD) deficiency
  17. Current or prior treatment with potent inhibitors of Dihydropyrimidine Dehydrogenase (DPD)
  18. (ARM VII): Prior exposure to BOLD-100
  19. (ARM VII): Subjects with microsatellite-high (MSI-H) Tumours
  20. (ARM VII): Concurrent monoclonal antibody therapy for mCRC (anti-EGFR, anti-VEGF or anti-)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Part B - Dose Expansion - 1L Gastric Cancer (ARM I)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Experimental
    Part B - Dose Expansion - 2L Gastric Cancer (ARM II)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Experimental
    Part B - Dose Expansion - 2L Pancreatic Cancer (ARM III)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Experimental
    Part B - Dose Expansion - 2L Colorectal Cancer (ARM IV)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Experimental
    Part B - Dose Expansion - 2L Cholangiocarcinoma (ARM V)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Experimental
    Part B - Dose Expansion - 3L Colorectal Cancer (ARM VI)

    Arm closed to enrollment.

    Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

  • Active comparator
    Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIA)

    Arm open to enrollment. 500 mg/m2 BOLD-100 + SOC (FOLFOX ± Bevacizumab)

    Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)

  • Active comparator
    Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIB)

    Arm open to enrollment. 625 mg/m2 BOLD-100 + SOC (FOLFOX ± Bevacizumab)

    Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)

  • Active comparator
    Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIC)

    Arm open to enrollment. FOLFOX ± Bevacizumab alone.

    Drug: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)

Interventions

  • DrugBOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)

    Arm VIIA: 500 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIB: 625 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIC: FOLFOX ± Bevacizumab alone

  • DrugBOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)

    BOLD-100 at 625 mg/m2 combined with FOLFOX Chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events ([S]AEs)

    Arms I-VI: Primary outcome measure; Arm VII: Secondary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment

  2. Incidence of dose-limiting toxicities (DLT)

    Dose escalation only.

    Time frame: Screening to 4 weeks after first treatment

  3. Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results, ECOG performance status

    Arms I-VI: Primary outcome measure; Arm VII: Secondary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment

  4. Progression Free Survival (PFS): Arm VII

    Arm VII: Primary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

  5. Overall Response Rate (ORR): Arm VII

    Arm VII: Primary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

  6. Overall Survival (OS): Arm VII

    Arm VII: Primary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

Secondary outcomes

  1. Progression Free Survival (PFS): Arms I-VI

    Arms I-VI: Secondary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

  2. Overall Response Rate (ORR): Arms I-VI

    Arms I-VI: Secondary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

  3. Overall Survival (OS): Arms I-VI

    Arms I-VI: Secondary outcome measure

    Time frame: Through study completion, approximately 2 weeks after last treatment for last patient

  4. Baseline and changes in biomarker levels during treatment

    Serum GRP78

    Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment

  5. Peak Plasma Concentrations (Cmax)

    Arms I-VII

    Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment

  6. Area under the plasma concentration versus time (AUC)

    Arms I-VII

    Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment

  7. Elimination half life (T1/2)

    Arms I-VII

    Time frame: Arms I-VII; Through study completion, approximately 2 weeks after last treatment

Other outcomes

  1. Quality of life evaluation

    Arm VII

    Time frame: Through study completion, approximately 2 weeks after last treatment

  2. Changes in dose reductions, treatment discontinuations, and interruptions, and AE's reported related to neuropathy from baseline

    Arm VII

    Time frame: Through study completion, approximately 2 weeks after last treatment

  3. Cancer mutational status in blood and tissue biomarker relationship to clinical outcomes

    Circulatory tumor DNA (ctDNA) collection will be tested for a panel of tumor mutations, genomic alterations, microsatellite instability and tumor mutational burden, and these will be associated to clinical outcomes, including overall survival, progression-free survival, overall response rate and other outcome measures

    Time frame: Arm VII; Through study completion, approximately 2 weeks after last treatment

  4. GRP78 levels and relationship to clinical outcomes

    Optional biopsy samples at screening and at cycle 4 will be collected and analyzed for GRP78 levels, other related pathway markers, immune cell profiles, and cancer mutation profiles, and comparing these to clinical outcomes including overall survival, progression-free survival, overall response rate and other outcome measures

    Time frame: Arm VII; Through study completion, approximately 2 weeks after last treatment

07

Study locations

26 of 28 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Jul 2027, 82 months after the start.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 82 months is above that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jun 2026 → Jul 2027 and completion Sep 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
Jun 9, 2020
StartActual
Aug 28, 2020
Primary completionEst.
Jul 1, 2027was Jun 2026
CompletionEst.
Dec 31, 2027was Sep 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added — first site in United Kingdom. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Fondazione IRCCS "Istituto Nazionale dei Tumori · Milan, ItalyNot yet recruiting→Recruiting
  • AOU L. Vanvitelli · Naples, ItalyNot yet recruiting→Recruiting
  • Azienda Ospedaliero Universitaria Pisana · Pisa, ItalyNot yet recruiting→Recruiting
  • Vall Hebron Institute of Oncology (VHIO) · Barcelona, SpainNot yet recruiting→Recruiting
  • Early Phase Unit FJD START Madrid · Madrid, SpainNot yet recruiting→Recruiting
  • Hospital 12 de Octubre · Madrid, SpainNot yet recruiting→Recruiting
Show 4 added (4 United Kingdom)
  • Velindre Cancer Centre Clinical Trials · Cardiff, United Kingdom
  • Ulster Hospital · Dundonald, United Kingdom
  • Royal Marsden Hospital · London, United Kingdom
  • Royal Marsden Hospital · Sutton, United Kingdom
Oct 28, 2026
Primary completion
Jun 1, 2026→Jul 1, 2027
Oct 28, 2026
Study completion
Sep 1, 2026→Dec 31, 2027
Oct 28, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHistologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and are subject to receive FOLFOX ± Bevacizumab. (ARM VII): Patients must have received only 1 prior line of therapy in the metastatic setting.
Exclusion criteria
  • EditedPrevious intolerance to or significant reaction secondary to fluorouracil, oxaliplatin, or oxaliplatinbevacizumab.
Oct 28, 2026
Interventions
Changed BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)→BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
Oct 28, 2026
Title
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    4 sites added — first site in United Kingdom. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Fondazione IRCCS "Istituto Nazionale dei Tumori · Milan, ItalyNot yet recruiting→Recruiting
    • AOU L. Vanvitelli · Naples, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliero Universitaria Pisana · Pisa, ItalyNot yet recruiting→Recruiting
    • Vall Hebron Institute of Oncology (VHIO) · Barcelona, SpainNot yet recruiting→Recruiting
    • Early Phase Unit FJD START Madrid · Madrid, SpainNot yet recruiting→Recruiting
    • Hospital 12 de Octubre · Madrid, SpainNot yet recruiting→Recruiting
    Show 4 added (4 United Kingdom)
    • Velindre Cancer Centre Clinical Trials · Cardiff, United Kingdom
    • Ulster Hospital · Dundonald, United Kingdom
    • Royal Marsden Hospital · London, United Kingdom
    • Royal Marsden Hospital · Sutton, United Kingdom
    Primary completion Jun 1, 2026→Jul 1, 2027
    Study completion Sep 1, 2026→Dec 31, 2027
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHistologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and are subject to receive FOLFOX ± Bevacizumab. (ARM VII): Patients must have received only 1 prior line of therapy in the metastatic setting.
    Exclusion criteria
    • EditedPrevious intolerance to or significant reaction secondary to fluorouracil, oxaliplatin, or oxaliplatinbevacizumab.
    Interventions Changed BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)→BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
    Title BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
    + 4 other changes: verification date, description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04421820
Lead sponsor
Bold Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Aug 28, 2020
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Michelle Jones
Contact
clinical@bold-therapeutics.com
604-262-9899
Jim Pankovich
Contact
jp@bold-therapeutics.com
604-262-9934

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion